Ticker Scorecard - RGNX Basics Company: REGENXBIO Inc. IPO Date: September 17, 2015 Sector: Healthcare Industry: Biotech Market Cap: $360.19M Activated in VL: True Average Daily Range Avg Daily Range: $0.81 | 2.82% Avg Daily Range (30 D): $0.17 | 2.18% Avg Daily Range (90 D): $0.28 | 3.11% Institutional Daily Volume Avg Daily Volume: .35M Avg Daily Volume (30 D): .73M Avg Daily Volume (90 D): .75M Trade Size Avg Trade Size (Sh.): 74 Avg Trade Size (Sh.) (30 D): 76 Avg Trade Size (Sh.) (90 D): 75 Institutional Trades Total Inst.Trades: 3,111 Avg Inst. Trade: $1.99M Avg Inst. Trade (30 D): $1.29M Avg Inst. Trade (90 D): $1.85M Avg Inst. Trade Volume: .07M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.3M Avg Closing Trade (30 D): $.84M Avg Closing Trade (90 D): $1.54M Avg Closing Volume: 79.65K     News Feb 21, 2025 @ 6:00 PM Cell and Gene Therapies in Rare Disorders Market t... Source: Delveinsight Feb 18, 2025 @ 6:00 PM Mucopolysaccharidosis Market Analysis Across 7MM Ã... Source: Delveinsight Jan 2, 2025 @ 7:30 AM Global Mucopolysaccharidosis Treatment Market to W... Source: Sabyasachi Ghosh (Associate Vice President At Future Market Insights, Inc.) Aug 30, 2024 @ 12:59 PM Gene Therapy Market Size to Reach USD 54.39 Billio... Source: Sns Insider Jun 25, 2024 @ 4:54 PM Why Is Clearside Biomedical Stock Gaining Today? Source: Vandana Singh Financials   TTM Q3 2024 Q2 2024 Basic EPS $-5.01 $-1.17 $-1.05 Diluted EPS $-5.01 $-1.17 $-1.05 Revenue $ 84.33M $ 24.2M $ 22.3M Gross Profit $ 45.84M $ 11.81M $ 11.72M Net Income / Loss $ -238.81M $ -59.6M $ -52.99M Operating Income / Loss $ -245.88M $ -62.08M $ -56.04M Cost of Revenue $ 38.49M $ 12.39M $ 10.58M Net Cash Flow $ 3.35M $ -1.15M $ -55.21M PE Ratio